The high unmet medical need in the market has driven the R&D activities of vendors, thereby fueling the new therapies in the market.
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five vendors for the global chemotherapy-induced nausea and vomiting (CINV) drugs market in their latest research report. This report also lists 24 other prominent vendors who are expected to contribute to this market’s growth between 2017-2021.
Competitive vendor landscape
The global CINV drugs market is highly fragmented in nature and is characterized by the presence of several players. Vendors in the market space compete on the basis of factors such as product efficacy, prolonged action, rich pipeline, limited side effects, and operational base and focus on increasing their sales volume by direct sales and through distributors. Advances in R&D activities and launch of novel therapies is expected to further intensify the competition in the global market for CINV drugs during the forecast period.
According to Barath Palada, a lead analyst at Technavio for research on central nervous system, “Vendors are focusing on developing drugs that improve patient compliance significantly. This initiative has driven the launch of oral therapies in the market, which are expected to witness an increased adoption in the coming years.”
Click here to request a free sample of this report
Top five vendors in the CINV drugs market space
GlaxoSmithKline
GlaxoSmithKline undertakes the manufacturing and marketing of pharmaceutical products, which include over-the-counter (OTC) products, vaccines, and health-related consumer products worldwide. The company leverages on its robust R&D and manufacturing network to foster its business activities.
Key products: Zofran.
Helsinn
Helsinn is involved in the development, manufacturing, and distribution of a range of pharmaceutical products across various therapy areas such as oncology. During March 2016, Helsinn and Eisai announced a revised agreement for their CINV franchise. Under the terms of the agreement, Helsinn Therapeutics, the US affiliate of Helsinn, will have exclusive rights to promote and market Akynzeo for the prevention of CINV.
Key products: Aloxi and Akynzeo.
Heron Therapeutics
Heron Therapeutics is a specialty pharmaceutical company that focuses on the development and marketing of innovative medical treatments harnessing its proprietary polymer-based technology. The company leverages on its robust R&D activities to develop new drugs. During 2015, the company spent almost USD 62 million on its R&D.
Key products: SUSTOL.
Merck
Merck undertakes the R&D, manufacturing, and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. As of FY2015, the company had a recorded revenue of more than USD 39 billion and spent almost USD 7 billion on R&D.
Key products: EMEND.
Tesaro
Tesaro is a biopharmaceutical company that focuses on the development of drugs primarily for the treatment of oncology. In November 2015, the company launched VARUBI in the US for the prevention of delayed nausea and vomiting linked with initial and repeat courses of emetogenic cancer chemotherapy
Key products: VARUBI.
Ask an analyst to know more about this report
A more detailed analysis is available in the Technavio report, Global CINV Drugs Market 2017-2021. Technavio also customizes reports by other regions and specific segments upon request.
Browse related reports
- Global Multiple Myeloma Drugs Market 2017-2021
- Global Lung Cancer Therapeutics Market 2016-2020
- Global Protein Therapeutics Market 2017-2021
To read more press releases – click here
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
